NCT05884190 Trauma-informed Approach to Timely Detection and Management of Early Postpartum Hypertension
| NCT ID | NCT05884190 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yale University |
| Condition | Postpartum Hypertension |
| Study Type | INTERVENTIONAL |
| Enrollment | 6,030 participants |
| Start Date | 2023-06-12 |
| Primary Completion | 2027-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 6,030 participants in total. It began in 2023-06-12 with a primary completion date of 2027-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators primary project goal is to improve clinical outcomes, including mental health outcomes, among postpartum at-risk women experiencing health disparities by increasing awareness, detection, and timely care of postpartum hypertension, mental health and cardiovascular complications. The investigators will accomplish this by comparing the effectiveness of two multi-component multi-level healthcare delivery models focused on early detection and control of postpartum hypertension and the social and mental health factors known to impact maternal outcomes, with the current standard of care and with each other.
Eligibility Criteria
Inclusion Criteria: * Delivery of singleton live birth (twins reduced to singleton or with vanishing twin syndrome prior to 14 weeks qualify) * Postpartum * English or Spanish speaking * Viable pregnancy 24 weeks of gestation or above (Child can be in NICU to participate) * Medicaid or the equivalent within each state (for example, Connecticut has Husky insurance) or uninsured * Must living in one of the three states involved in this study (Connecticut, Massachusetts, New York) and preferably within the geographical area of each of the hospitals Exclusion Criteria: * Multifetal pregnancy (since are they at increased risk for key outcomes) * Gestational age \<24 weeks; * Known major fetal anomaly in current pregnancy or stillbirth * Actively using illicit/illegal substances (such as cocaine, heroin and other types of illicit opiates such as fentanyl) as noted in delivery hospitalization notes * Active suicidal ideation with intent and plan * Known primary psychotic disorder (i.e. schizophrenia, or schizoaffective disorder) * Plans to move out of the state within 6 months * Incapable of consent * Severe medical complications that don't allow a mother to do the study effectively (for example, active treatment for cancer, dialysis etc. ) * Physician or provider refusal * Patient refusal * Incarcerated or institutionalized * Stillbirth Births that result in the newborn being under the care of another person or institution other than the birthing individual (e.g. adoption, state involvement) will be evaluated on an individual basis to determine if that person should be included. For participants without access to a phone, we will explore if there are options that will allow them to have access to a devise for the times when they need to communicate with the study team. If not, they will not be able to participate in the study since this study requires phone or telehealth communication with research staff and/or APPs, and CHWs depending on study phase.
Contact & Investigator
Rafael Pérez-Escamilla, PhD
PRINCIPAL INVESTIGATOR
Yale University
Frequently Asked Questions
Who can join the NCT05884190 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Postpartum Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05884190 currently recruiting?
Yes, NCT05884190 is actively recruiting participants. Contact the research team at rafael.perez-escamilla@yale.edu for enrollment information.
Where is the NCT05884190 trial being conducted?
This trial is being conducted at New Haven, United States, Worcester, United States, Buffalo, United States.
Who is sponsoring the NCT05884190 clinical trial?
NCT05884190 is sponsored by Yale University. The principal investigator is Rafael Pérez-Escamilla, PhD at Yale University. The trial plans to enroll 6,030 participants.